Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Hansoh Pharmaceutical Group Company Limited (3692.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
15.800-0.080 (-0.50%)
At close: 04:08PM HKT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close15.880
Open15.800
Bid15.780 x N/A
Ask15.800 x N/A
Day's Range15.700 - 16.060
52 Week Range12.000 - 26.350
Volume1,777,800
Avg. Volume4,439,646
Market Cap93.573B
Beta (5Y Monthly)0.30
PE Ratio (TTM)30.98
EPS (TTM)0.510
Earnings DateMar 30, 2021
Forward Dividend & Yield0.09 (0.57%)
Ex-Dividend DateJun 16, 2022
1y Target Est25.73
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 3692.HK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Newsfile

      Kodiak Intersects Shallow Higher-Grade Copper Gold Mineralization in First Holes at Dillard, Confirms Significant Porphyry Target: 0.63% CuEq over 21.0 m, Within 0.23% CuEq over 381.1 m

      Vancouver, British Columbia--(Newsfile Corp. - May 4, 2022) - Kodiak Copper Corp. (TSXV: KDK) (OTCQB: KDKCF) (FSE: 5DD1) (the "Company" or "Kodiak") today reports drill results from the 100% owned MPD copper-gold porphyry project in southern British Columbia. Results from the final seven holes drilled at MPD in 2021 are presented in this release. The fully funded 2022 drill program of up to 25,000 metres is now underway.The Company's first two holes testing the ...

    • Bloomberg

      The Unsung Winners and Biggest Losers of China's Rocky Markets in 2021

      (Bloomberg) -- In a year that’s seen China’s “common prosperity” agenda roil global equity markets, the nation’s policies also created a greater divide between stock winners and losers at home.Most Read from BloombergWHO Downplays Threat of Covid-19 Variant Found in FranceU.S. Logs Record 1 Million Virus Cases With Data DelayOmicron Cases Are Hitting Highs, But New Data Put End in SightHong Kong Scraps Flights, Shuts Bars, Gyms on Omicron ThreatHong Kong Vaccine Surge Sees Majority Pick Sinovac

    • GlobeNewswire

      Keros Therapeutics Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to KER-050 in China

      Keros Therapeutics to receive potential milestone payments up to $170.5 million, $20 million upfront, and tiered royalty payments in the low double digit to high teens on net product sales LEXINGTON, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unm

    Advertisement
    Advertisement